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1. Introduction 
Mood disorders are characterized by depression, mania, or both. There are two groups of 
mood disorders, depressive disorders and bipolar disorder. Bipolar disorder is 
characterized by intermittent episodes of mania or hypomania and depressive episodes; 
rapid cycling, mixed states, and psychotic symptoms occur in some cases. Depression is a 
serious mental disorder that manifests with depressed mood, loss of interest or pleasure, 
feelings of guilt or low self-worth, disturbed sleep or appetite, low energy, and poor 
concentration. Mania is the opposite of depression; it is a state of abnormally elevated or 
irritable mood, arousal, and/or energy levels. Depression and mania are thought to be 
heterogeneous illnesses that can result from dysfunction of several neurotransmitter or 
metabolic systems. 
The base of biological psychiatry is an assumption that human mind is connected with 
human body so that mental disorders (processes) are accompanied with biochemical 
changes, which can be measured. The second issue of biological psychiatry is a causality of 
all natural processes, including human mind. Molecular psychiatry studies disorders in 
human mind from the neurochemical, neurophysiological, neuroendocrine and genetic 
point of view mainly. It is postulated that mood disorders are caused by or associated with 
the disturbance of nervous signal transmission in the brain at the level of chemical synapses. 
On the molecular level, there is impaired neurotransmission mediated by neurotransmitters, 
their receptors and transporters, and by intracellular processes coupled to the activation of 
receptors for neurotransmitters and growth factors.  
Because of difficult availability of human brain tissue for neurochemical measurements, 
psychotropic drugs effects are studied with the purpose to select those components of 
intracellular signalling pathways, which could be responsible for the therapeutic effects of 
tested drugs and consequently be related to origin of the disease. Results support the 
hypothesis that the treatment with antidepressants, mood stabilizers and even some 
antipsychotics leads to effects similar to neurotrophic and anti-inflammatory. Due to 
feedbacks inside the neuron the attention is devoted to pathways connected with receptors 
for monoamine neurotransmitters, receptors with inner calcium channel, and receptors for 
neurotrophins or Wnt glycoproteins. The role of neurochemical hypotheses of mood 
disorders is to suggest the relationship between symptoms of the disease, changes in 
signalling pathways and mechanisms of action of psychotropic drugs. 
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Understanding of neurochemistry of mood disorders as well as molecular mechanisms of 
action of antidepressants and mood stabilizers are necessary to declare valid molecular 
theory of the disorder as basis of effective diagnosis, prevention and treatment. However, 
sensitive and specific genetic, biochemical, physiological, neuroendocrine or other biological 
tests have not been so far developed to be capable for diagnosis of mood disorders and their 
subtypes or for prediction of efficacy of current pharmacotherapy. It seems that leading role 
in neurochemistry of mood disorders could be awarded to disturbed monoamine 
neurotransmission, dysfunction in energy metabolism of neurons, modulation of 
inflammatory pathway, and changes in activities of transcription factors, neurotrophic 
factors and other components involved in neuroplasticity and apoptosis. 
Basic findings about signalling pathways included both in pathophysiology of mood 
disorders and in mechanisms of action of administered psychotropic drugs are summarized 
in this chapter. Finally, there are summarized advances in neurochemical hypotheses of 
mood disorders.  
2. Synaptic signal transduction 
Synaptic signal transduction is complex process by which a neurotransmitter (extracellular 
signalling molecule) is released in response to action potential or other stimuli and activates 
a specific membrane receptor that leads to alteration of intracellular molecules forming a 
cellular response. Signal transduction system consists of many components 
(neurotransmitters, specific receptors, ion channels, G proteins, effector enzymes, 
transporters and other membrane proteins, second messengers, protein kinases, 
phosphatases, transcription factors, neurotrophic factors etc.) and numberless interactions, 
interconnections and feedbacks among them. Structure and composition of lipid bilayer also 
plays an important role, because of the fact that most of membrane proteins require 
interaction with specific phospholipids or with cholesterol for their optimal function. 
Signalling pathways included in the pathogenesis of mood disorders are primarily activated 
mostly by serotonin (5-hydroxytryptamine, 5-HT), norepinephrine, dopamine, glutamate 
and Ǆ- aminobutyric acid (GABA), i.e. they are connected with the processes in adenylate 
cyclase and phosphoinositide systems and with changes of intracellular ion concentrations, 
especially with calcium. Only selected components of signalling pathways are presented 
supposed to play a key role in pathophysiology and neurochemistry of mood disorders. 
2.1 Neurotransmitters 
A multitude of chemicals called neurotransmitters mediate intercellular communication in 
the nervous system. There are several groups of neurotransmitters: classical 
neurotransmitters, neuropeptides, endocannabinoids, nitric oxide (NO), and carbon 
monoxide (CO). Although they exhibit great diversity in many of their properties, most of 
them are stored in vesicles in nerve terminals (except for endocannabinoids, NO and CO) 
and are released to the extracellular space via processes requiring calcium ions. Their action 
is terminated by reuptake into presynaptic terminal or glia cells or by catabolism in 
extracellular space (e.g. in synaptic cleft) or in presynaptic terminal.  
All classical neurotransmitters are synthesized in nerve terminals. The first molecule to be 
implicated as neurotransmitter was acetylcholine (ACh). ACh is synthesized from choline 
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and acetyl-coenzyme A in the nerve endings; reaction is catalyzed by the enzyme choline 
acetyltransferase. ACh is rapidly degraded in synaptic cleft by the enzyme 
acetylcholinesterase. 
There are three major amino acid neurotransmitters in the nervous system: GABA, glycine 
and glutamic acid. GABA and glycine are inhibitory neurotransmitters; glutamate and 
aspartate are excitatory neurotransmitters. 
Monoamine neurotransmitters, such as dopamine, norepinephrine or serotonin are the most 
important neurotransmitters in pathophysiology of mood disorders and in mechanisms of 
action of antidepressants. Catecholamines (dopamine, norepinephrine and epinephrine) are 
synthesized from tyrosine. Dopamine is formed by tyrosine hydroxylase catalysed 
hydroxylation (rate limiting step) and decarboxylation of tyrosine. Norepinephrine is 
formed by hydroxylation of dopamine in presence of dopamine ǃ-hydroxylase. Indolamines 
(serotonin and tryptamine) are synthesized from tryptophan by hydroxylation and 
decarboxylation; tryptophan hydroxylase mediated reaction is the rate-limiting step. Action 
both of catecholamines and indolamines on target cells is terminated much more slowly 
than that of acetylcholine; they are removed from synaptic cleft by reuptake. The major 
enzymes involved in the catabolism of catecholamines are monoamine oxidase (MAO) and 
catechol-O-methyltransferase (COMT). Serotonin is metabolized by MAO. 
A great number of neuropeptides have been discovered and new neuropeptides being 
identified continually. All neuropeptides are synthesized in the cell body. The action of 
neuropeptides in the synaptic cleft is terminated by peptidases; there is no reuptake for 
neuropeptides. Neuropeptides usually act as co-transmitters and their transduction 
mechanism is coupled with G proteins.  
The endocannabinoids are a family of lipid neurotransmitters that mediate retrograde signal 
from postsynaptic neurons to presynaptic ones (Fišar, 2009). Nitric oxide and carbon 
monoxide have specific properties from among neurotransmitters, since the NO or CO does 
not interact with membrane receptors but diffuse to target intracellular receptor (Hill et al., 
2010; Snyder & Ferris, 2000). Abundant recent evidence favours a 
neurotransmitter/neuromodulator role for D-serine, because the D-serine, rather than 
glycine, is the endogenous ligand for N-methyl-D-aspartate (NMDA) receptors in many 
brain structures. D-serine is synthesized mainly in glial cells and it is released upon 
activation of glutamate receptors (Oliet & Mothet, 2009). 
2.2 Growth factors 
Growth factors are proteins that stimulate cellular growth, proliferation and differentiation, 
and promote cellular survival. They are essential for development and function of nervous 
system and have important function in neurotransmission. They are released from different 
cells; after interaction with membrane receptors changes in activity of intracellular enzymes 
occur leading to changes in gene expression and production of cellular molecules. 
Mechanism of their action is similar to action of neurotransmitters, but they are not released 
in response to membrane depolarization and to changes of intracellular calcium levels. 
Growth factors that promote the survival, development and function of neurons are known 
as neurotrophic factors. From the psychiatric point of view neurotrophins are the most 
important class of growth factors.  
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Neurotrophic factors act by preventing the neuron from initiation of programmed cell death 
(apoptosis); they induce differentiation of progenitor cells to form neurons. The term 
”neurotrophin“ is reserved for four structurally related neurotrophic factors: nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and 
neurotrophin-4 (NT-4). Each of four neurotrophins activates one or more of three trk 
(tropomyosin-related kinase) receptors with intracellular tyrosine kinase activity called 
trkA, trkB and trkC. Furthermore, each neurotrophin can still bind (with low affinity) to 
neurotrophic receptor p75 (p75NTR), homologous to tumour necrosis factor (TNF) and 
without any tyrosine kinase activity. 
BDNF has a key role in stress response and in action of antidepressants. Exposure to stress 
has been shown to decrease the expression of BDNF. Series of studies support the 
hypothesis that a reduction of BDNF could contribute to depression and that 
antidepressants mediate their therapeutic benefits by increasing levels of this factor in the 
hippocampus (Castrén et al., 2007; Castrén & Rantamäki, 2008; Duman & Monteggia, 2006). 
2.3 Neurotransmitter receptors 
Receptor is macromolecule specialized on transmission of information. It is defined as 
binding site with functional relationships. Receptor complex includes: 1. Specific binding 
site; 2. Internal ion channel or transduction element; 3. Effector system (ion channel or 
system of second messengers). Activation of receptors with internal ion channel leads to 
rapid change in membrane potential and to prompt cellular response. Activation of 
receptors coupled with G proteins leads to slower response through activation of effector 
system. Effector system includes G protein activated ion channels or enzymes; G protein 
activated enzymes generate second messengers, which activate protein kinases. Protein 
phosphorylation plays a significant role in a wide range of cellular processes. Transcription 
factors can be phosphorylated too, and phosphorylated transcription factors serve as third 
messengers, which activate gene expression. 
Receptors are able to adapt their properties to increased or decreased activation. Changes in 
the density of receptors are known mechanism of their adaptation (receptor down-
regulation or up-regulation). Additionally, response to receptor activation can be altered at 
unchanged density of receptors, because regulation of properties of receptors may consist of 
decreased or increased activity of post receptor events (desensitization or hypersensitivity). 
2.4 Neurotransmitter transporters 
Neurotransmitter transporters are necessary for synaptic transmission just as receptors, ion 
channels, G proteins and effectors. Generally, neurotransmitters are removed from synaptic 
cleft by enzymatic degradation or by active transport to presynaptic button or to 
surrounding glia cells. There are three main classes of membrane transporters: 1. 
Transporters dependent on sodium and chlorine transport serotonin, norepinephrine or 
dopamine back into presynaptic part; this enables that neurotransmitters may be stored in 
vesicles and repeatedly released in response to action potential; 2. Vesicular transporters 
carry neurotransmitters into synaptic vesicles; 3. Sodium dependent transporters are 
localized in the membrane of glia cells and transport neurotransmitters such as GABA, 
glutamate or aspartate into glia cells. 
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Functional polymorphisms in the promoter region of the serotonin transporter (SERT, 5-
HTT) gene and BDNF gene were found to moderate the influence of stressful life events on 
depression (Aguilera et al., 2009; Caspi et al., 2003). 
2.5 Postreceptor events 
It is assumed that signal transduction mediated by receptors associated with G proteins and 
2nd messenger systems are altered at mental disorders and during treatment with 
psychotropic drugs. After activation of receptor by first messenger G proteins are activated 
and activated G proteins activate effectors enzymes, such as adenylyl cyclase or 
phospholipase C, and second messengers are produced. Second messenger activates protein 
kinase of type A, C or calmodulin (CaM) dependent, which catalyses phosphorylation of 
cellular proteins and physiological response to receptor activation arises. Second 
messengers generated by enzymes activated by G proteins include cyclic adenosine 
monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), inositol trisphosphate 
(IP3), diacylglycerol (DAG), calcium (Ca2+), metabolites of arachidonic acid and nitric oxide. 
There are many neurotransmitters, many receptors, less G proteins and a few effector 
systems. However, there are many feedbacks at the cellular level and many cross-reactions 
at the intracellular level. Individual signalling systems interact together and form complex 
intracellular system, which enables neurons to compile signals from the different 
neurotransmitter systems, and which is involved in regulation of neuroplasticity and stress 
response. Reversible phosphorylation of proteins is probably the crucial molecular 
mechanism, which is used to realize the biological response to extracellular signals in target 
neurons. Attention is paid to cAMP dependent protein kinases (PKA), protein kinases C 
(PKC) activated by DAG, protein kinases dependent on calcium and calmodulin (CaMK), 
and protein kinases B (PKB, Akt). Transcription factor CREB, neurotrophin BDNF, glycogen 
synthase kinase-3 (GSK-3) and components regulating programmed cell death, especially 
family of Bcl-2 proteins and various mitochondrial factors (including MAO, enzymes of 
respiratory chain and mitochondrial DNA) are intensively studied, as well. 
2.5.1 Monoamine oxidase 
The enzyme monoamine oxidase (MAO; EC1.4.3.4) is a mitochondrial enzyme, which 
catalyzes oxidative deamination of biogenic and xenobiotic monoamines. It regulates the 
metabolic degradation of catecholamines and serotonin in neural and other target tissues. 
Major physiological role of intraneuronal MAO is to keep cytosolic monoamine 
concentrations very low. MAO exists in two isoforms that differ in substrate preference, 
inhibitor specificity, tissue and cell distribution, and immunological properties (Bach et al., 
1988). The type A (MAO-A) metabolizes 5-HT and is sensitive to inhibition by low 
concentrations of clorgyline, whereas the type B (MAO-B) prefers benzylamine or 2-
phenylethylamine as substrates and is sensitive to inhibition by low concentrations of l-
deprenyl. Tyramine, tryptamine, dopamine, norepinephrine and epinephrine are equally 
well oxidized by both isoforms of MAO (Youdim et al., 2006). The high levels of both forms 
are found in the brain; MAO-B is found in dopamine-secreting neurons in the brain.  
MAOs have an important role in brain development and function, and MAO inhibitors 
have a range of potential therapeutic uses (Ramsay & Gravestock, 2003). Generally, 
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selective inhibitors of MAO-A and nonselective MAOIs seem to be effective in the 
treatment of patients with depression, panic disorder, and other anxiety disorders (Stahl 
& Felker, 2008). It is supposed that MAO-B inhibition may slow the course of various 
neurodegenerative disorders; thus, selective inhibitors of MAO-B may be efficacious in 
treatment of Parkinson’s disease (Horstink et al., 2006) and possibly of Alzheimer's 
disease (Riederer et al., 2004). 
2.5.2 Transcription factor CREB 
The allocation of information and memory to specific cells and synapses within a neural 
network is modulated by many synaptic, cellular, and intercellular components and by 
mechanisms working at different time scales (Silva et al., 2009). The transcription factor 
CREB (cyclic adenosine monophosphate response element binding) regulates transcription 
of many genes and has a well-known role in the learning related to synaptic plasticity 
(Carlezon et al., 2005). CREB is also involved in antidepressant response (Chen et al., 2001). 
Increase in CREB function can enhance memory; however, cognitive performance can be 
disrupted under some circumstances. CREB activity has sometimes beneficial, sometimes 
detrimental roles, depending on the brain region involved. Therefore, alterations in CREB 
function do not produce uniform effects throughout the brain (Blendy, 2006; Carlezon et al., 
2005; Tardito et al., 2006). 
2.5.3 Bcl-2 
Bcl-2 (acronym for B-cell CLL/lymphoma 2) protein family is included in the regulation of 
apoptotic cell death and is formed from members with both antiapoptotic (e.g. Bcl-2, Bcl-xL, 
Bcl-w) and proapoptotic (e.g. Bax, BAD, Bak) activities. There are a number of theories 
concerning how members of the Bcl-2 family exert their effects. E.g., proteins from Bcl-2 
family together with other factors control the permeability of mitochondrial membranes 
(Chipuk & Green, 2008). The main changes in mitochondria during apoptosis are 
mitochondrial outer membrane permeabilization MOMP (regulated by members of Bcl-2 
family) and depolarization of inner membrane. Bcl-2 itself is antiapoptotic; it reduces 
apoptosis by sequestration of caspases, by inhibition of release of mitochondrial apoptotic 
factors and by increasing of calcium uptake into the mitochondria. It is supposed that 
neurodegenerative diseases, including schizophrenia and mood disorders, may result from 
an abnormal ratio or function of pro- and antiapoptotic factors. 
2.5.4 Glycogen synthase kinase 3 
Glycogen synthase kinase 3 (GSK-3) is serine/threonine kinase that phosphorylates 
glycogen synthase and many other substrates such as transcription factors, enzymes and 
cytoskeletal elements. In human, it occurs in 2 isoforms, GSK-3ǂ and GSK-3ǃ; biological 
functions of ǃ isoform have been more analyzed, it is widely present in the brain. Role of 
GSK-3 was found in different diseases, Alzheimer’s disease, diabetes mellitus type 2, 
various carcinomas (Peineau et al., 2008), as well as in pathophysiology and treatment of 
bipolar disorder (Gould et al., 2007). Activity of GSK-3 is regulated by phosphorylation; 
phosphorylation on tyrosine residues increases the enzyme efficiency, phosphorylation of 
final serine has inhibitory effects. Furthermore, GSK-3 can be inactivated by stimuli coming 
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from different signalling pathways, e.g. Wnt pathway (Fig. 5), phosphoinositide 3-kinase 
(PI3K) pathway, from PKA, PKC or from others. Main signalling pathways modulated by 
GSK-3 are insulin pathway, pathway of neurotrophic factors and Wnt pathway. 
Different antidepressants, antipsychotics, amphetamines and growth factors have direct or 
indirect effects on GSK-3 and GSK-3 mediated signalling pathways. From the view of 
biological psychiatry, there is an important finding that GSK-3 is directly inhibited by 
lithium (by competition with Mg2+ ions) and indirectly inhibited with valproate; both of 
them are used in the treatment of bipolar disorder. GSK-3 inhibition is antiapoptotic, 
because of generally proapoptotic action of GSK-3. The hypothesis is tested that lithium 
(and other medications) can due to the GSK-3 inhibition induce cellular processes leading to 
changes in bioenergetics, neuroplasticity, neurogenesis, stability and survival of neurons 
(Gould & Manji, 2005). 
3. Signalling pathways 
There is relatively small amount of signalling pathways initiated by activation of membrane 
receptors, which leads to the majority of important intracellular physiological processes. 
Their modulations influence gene expression and the function of cellular proteins, the 
change of synaptic functions, neuroplasticity and the response to neurotransmitters, 
neuropeptides, neurohormones, glucocorticoids and other bioactive molecules. 
Understanding of these signalling pathways is essential for insight to pathogenesis and 
pathophysiology of mood disorders (Fišar & Hroudová, 2010). 
3.1 Adenylate cyclase pathway 
The mechanism of activation of the adenylate cyclase system is well known (Fig. 1). 
Neurotransmitter or other agonist binds to specific binding site of G protein-coupled 
receptor (GPCR) and activates G proteins. Main G proteins, regulating activation of 
adenylate cyclase (also known as adenylyl cyclase, AC), are Gs, Gq and Gi. Activated Gǂs or 
Gǂq subunits bind to AC and activate it directly; free ǃǄ complexes activate certain AC 
subtypes, as well. Activated AC catalyses conversion of ATP to cAMP; presence of Mg2+ 
ions is required and reaction is stopped by G protein inactivation. Gǂi subunits decrease 
intracellular cAMP levels by inhibition of AC. Indirectly, AC activity can be modulated 
through the activation of phosphoinositide system, when protein kinases C (PKC) and 
calcineurin are activated. cAMP activates cAMP-dependent protein kinases (PKA). cAMP 
decomposition into 5’-AMP is catalyzed by phosphodiesterase (PDE) in the presence of 
Mg2+. Activated PKA phosphorylates neuronal proteins; it leads to cross-connections of 
various signalling pathways and to different physiological effects (Sands & Palmer, 2008; 
Taylor et al., 2005). Phosphorylation (activation) of transcription factor CREB and 
consequent expression of neurotrophin BDNF seems to be important for therapeutic 
efficiency of antidepressants (Duman et al., 1997). Further, phosphorylation of nuclear factor 
κB (NFκB) is required for activation of transcription and interaction with CREB binding 
protein (CBP). NFκB obviously participates in survival of neurons (Hayden & Ghosh, 2004). 
PKA supports the neuronal survival by inhibition of proapoptotic factor BAD and by 
activation of NFAT (nuclear factor of activated T cells) protein (Wu et al., 2007). Importance 
of APC (anaphase-promoting complex) inactivation is also studied in processes of axon 
growth, neuronal survival and synaptic functions (Kim & Bonni, 2007). 
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AC – adenylate cyclase (adenylyl cyclase); AMP – adenosine monophosphate; APC – anaphase-
promoting complex; ATP – adenosine-5'-triphosphate; BAD – proapoptotic factor from Bcl-2 family 
(Bcl-2-associated death promoter); BDNF – brain-derived neurotrophic factor; cAMP – cyclic adenosine 
monophosphate; CBP – CREB binding protein; CREB protein – cAMP response element-binding 
protein; eNOS – endothelial nitric oxide synthase; ERK – extracellular signal-regulated kinase; GPCR – 
G protein-coupled receptor; GSK-3 – glycogen synthase kinase-3; NFκB – nuclear factor κB; NFAT – 
nuclear factor of activated T cells; PDE – phosphodiesterase; PKA – protein kinase A, cAMP dependent 
protein kinase; PKC – protein kinase C;  - activation;   - inhibition 
Fig. 1. Adenylate cyclase pathway (Fišar & Hroudová, 2010). Detailed description in the text. 
3.2 Guanylate cyclase pathway 
Guanylate cyclase (GC, also known as guanylyl cyclase) catalyses production of cyclic 
guanosine monophosphate (cGMP) from guanosine triphosphate (GTP); presence of Mg2+ is 
required. There are two types of GCs, soluble (sGC) and membrane (Fig. 2). Membrane-
bound form of GC is activated by peptide hormones; sGC is a receptor for nitric oxide (NO). 
The cGMP is a regulator of ion channels conductance, glycogenolysis and apoptosis; it also 
relaxes smooth muscles. cGMP degradation to 5’-GMP by phosphodiesterases (PDEs) is 
analogous to cAMP degradation. cGMP-dependent protein kinase (PKG) is activated by 
cGMP; PKG type I is expressed in specific brain regions. 
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ATP – adenosine-5'-triphosphate; CaM – calmodulin; cGMP – cyclic guanosine monophosphate; GC – 
guanylate cyclase (guanylyl cyclase); GTP – guanosine-5’-triphosphate; NO – nitric oxide; nNOS – 
neuronal nitric oxide synthase; PAK – p21 activated kinase; PDE – phosphodiesterase; PKG – protein 
kinase G; Rac – small G protein with GTPase activity; ROC – receptor-operated channel; sGC – soluble 
guanylate cyclase; VOC – voltage-operated channel;  - activation;   - inhibition 
Fig. 2. Guanylate cyclase pathway. Detailed description in the text. 
3.2.1 Membrane guanylate cyclase 
There are seven mammalian transmembrane GCs. GC-A and GC-B are natriuretic peptide 
receptors, GC-C can be activated by guanylin or uroguanylin (bacterial enterotoxins). The 
principal function of plasma membrane GCs in the CNS is modulation of sympathetic 
activity, inhibition of arginine vasopressin secretion, diminished salt appetite and water 
drinking, and effects on blood pressure/volume-regulating regions in the brain (Kuhn, 
2003). Signalling pathway that provides a general mechanism for diverse signalling 
receptors to increase the cGMP concentrations was supposed in following sequence (Fig. 2): 
1. Activation of membrane receptor, 2. Activation of Rac protein (small signalling G protein 
with GTPase activity) via guanine nucleotide-exchange factor, 3. Activation of p21 activated 
kinase (PAK) by Rac, 4. Activation of membrane GC by PAK, and 5. cGMP production (Guo 
et al., 2010). 
3.2.2 Soluble guanylate cyclase and nitric oxide 
In the brain, metastable free radical NO production is linked to the calcium (Ca2+) influx 
during membrane depolarization through voltage-operated channels (VOC), e.g. L-type 
calcium channels, or after activation of receptor-operated channels (ROC), e.g. NMDA 
ionotropic glutamate receptors. Calmodulin (CaM) is activated following the increase of 
intracellular calcium and neuronal NO synthase (nNOS, NOS-1) is activated by Ca2+/CaM; 
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nNOS catalyze conversion of arginine to NO and citrulline. NO regulates many kinds of ion 
channels, including voltage-gated (Jian et al., 2007) and ligand-gated Ca2+-channels. NO 
functions as a neurotransmitter by diffusing through the membranes of postsynaptic cells, 
where it binds in sGC and activates this enzyme to convert GTP into the cGMP (Snyder & 
Ferris, 2000). Thus, increased cGMP production could be attributed to NO, establishing a 
role for NO in mediating actions of glutamate in the brain. Two major signalling 
mechanisms, namely cGMP pathway and S-nitrosylation, mediate the cellular effects of NO. 
It has been reported that cGMP-mediated processes occurs at low NO concentrations, 
whereas S-nitrosylation occurs when NO is available at levels ranging from physiological to 
pathophysiological conditions. However, there are many other biological activities affected 
by NO (Brown, 2010; Thomas et al., 2008). 
NO-sensitive sGCs, PKGs, and cGMP-regulated PDEs have important functions as 
generators, effectors, and modulators of cGMP signals in the brain, respectively. The 
NO/sGC/cGMP/PKG pathway (Fig. 2) modulates long-term changes of synaptic activity in 
different brain regions. NO can modulate neuronal excitability and neurotransmitter release; 
thus, NO appears to play an important role in normal brain function and may have 
significant implications for the treatment of stress-related psychiatric disorders (Snyder & 
Ferris, 2000; Chiavegatto & Nelson, 2003). The human hippocampus contains a high density 
of NMDA receptors and neurons expressing nNOS suggesting that NMDA-NO 
transduction pathway can be involved in the pathogenesis of affective disorders and in the 
mechanism of action of antidepressants (Paul & Skolnick, 2003). It is well established that 
nNOS-derived NO inhibits neurogenesis (Zhu et al., 2006); moreover, several studies have 
indicated that nNOS inhibitors have antidepressant-like properties (Joca & Guimarães, 
2006). Furthermore, several reports have demonstrated that increased plasma NO 
metabolites levels were associated with suicide attempts, especially in depressive patients 
(Kim et al., 2006; Lee et al., 2006). Activation of the NOS in the hippocampus can be 
involved in the pathogenesis of affective disorders, possibly triggered by effects of stress on 
hypothalamic-pituitary-adrenal (HPA) axis and mediated by impaired serotonin function. 
3.3 Phosphoinositide pathway 
Phosphoinositide pathway includes activation of phosphoinositide phospholipases C (PLCs), 
which participate in phosphatidylinositol bisphosphate (PIP2) metabolism and lipid 
signalling pathways in a calcium-dependent manner (Fig. 3). PLCs are localized mostly in 
plasma membranes. PLC family contains 13 isoenzymes divided into six subfamilies. 
Neurotransmitter or agonist binds to receptor binding site and G proteins (mostly Gq/11, 
sometimes Go or Gi) are activated. Gǂq/11 subunits activate (Ca2+ is required) PLC, mostly 
PLCǃ isoform. GǃǄ subunits activate only isoenzymes PLCǃ2 and PLCǃ3. PLCǄ subtype is 
activated by both receptor (trk) and non-receptor tyrosine kinases, PLCǅ by elevated 
calcium levels, PLCǆ by Ras and Rho GTPases, PLCη by GǃǄ subunits (Stewart et al., 2007). 
Activated PLCs catalyze hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) and give 
arise to the second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG). DAG 
activates (in the presence of Ca2+) protein kinases type C (PKCs) and they phosphorylate 
many enzymes and other cellular proteins. IP3 binds to intracellular receptors (IP3R), leading 
to Ca2+ release from endoplasmic reticulum (ER). Ca2+ activates calmodulin (CaM), and 
Ca2+/CaM-dependent protein kinases (CaMKs) phosphorylate a wide range of neuronal  
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BDNF – brain-derived neurotrophic factor; CaM – calmodulin; CaMK – calcium and calmodulin-
dependent protein kinase; CBP – CREB binding protein; CREB protein – cAMP response element-
binding protein; DAG – diacylglycerol; ER – endoplasmic reticulum; GPCR – G protein-coupled 
receptors; IP3 – inositol 1,4,5-trisphosphate; IP3R – IP3 receptor; NFκB – nuclear factor κB; NFAT – 
nuclear factor of activated T cells; p300 - transcriptional co-activating protein; PIP2 – 
phosphatidylinositol 4,5-bisphosphate; PKC – protein kinase C; PLC – phosphoinositide phospholipase 
C, phospholipase C; Ras – small GTPase; Rho – small GTPase; trk – tropomyosin-related kinase;  
- activation;   - inhibition 
Fig. 3. Phosphoinositide pathway (Fišar & Hroudová, 2010). Detailed description in the text. 
proteins, including transcription factor CREB (with CBP and p300 as coactivators). 
Calcineurin, which dephosphorylates (activates) NFAT (nuclear factor of activated T cells) 
transcription factor, is also activated by CaM. 
Nervous tissue shows high PKC activities; there this enzyme system takes part in the 
regulation of ion channels, modulation of receptors, release of neurotransmitters, synaptic 
potentiation, synaptic depression, neuronal survival etc. Changes of activities and 
concentrations of PKC isoforms have been described in neurodegenerative diseases both 
acute (ischemia, trauma) and chronic (Alzheimer’s disease, Parkinson’s disease, 
amyotrophic lateral sclerosis) and by affective or psychotic disorders (Battaini, 2001; Pascale 
et al., 2007). A large range of biochemical data supports potential PKC involvement in 
pathophysiology of bipolar disorder and its treatment. 
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3.4 Calcium signalling pathway 
Neurotransmitter, hormone or growth factor as well as depolarization of the membrane in 
excitable cells are responsible for change of intracellular calcium (Berridge et al., 2000). 
Intracellular calcium concentrations are regulated by transporters, which remove Ca2+ from 
the cell or store them in mitochondria and endoplasmic reticulum (Fig. 4). Intracellular 
calcium concentrations increase after the opening of Ca2+ channels in plasma membrane in 
the response to membrane depolarization (VOC, voltage-operated channel) or in response to 
activation of ionotropic receptors (ROC, receptor-operated channel; e.g. NMDA receptor) or 
in the response to activation of inositol trisphosphate receptor (IP3R) in the membrane of 
endoplasmic reticulum (ER). Concentrations of cytosolic calcium are decreased both by 
transport from cell and by uptake into the mitochondria or endoplasmic reticulum. Plasma 
membrane Ca2+-ATPases (PMCA), sodium-calcium exchanger (NCX) and mitochondrial 
calcium transporter (mCU) are responsible for the depletion of cytosolic calcium. 
Mitochondrial NCX in reverse mode of operation participates in the influx of Ca2+ ions into 
matrix in pathological conditions such as brain ischemia. Following Ca2+ uptake into the 
mitochondria, Ca2+ is slowly released by mitochondrial NCX (Kann & Kovács, 2007). Ca2+ 
can be released also from ER, by Ca2+-activation of ryanodine receptor (RyR).  
Increased cytoplasmic calcium activates calmodulin (CaM) and consequently both 
calcineurin and Ca2+- and CaM-dependent protein kinases (CaMK) are activated. Cascade of 
calcium and CaM dependent protein kinases includes three kinases: kinase of CaM kinase 
(CaMKK) and CaM kinases CaMKI and CaMKIV which are activated by CaMKK. They 
occur frequently in the brain and T-lymphocytes. Nuclear CaMKIV regulates transcription 
through the phosphorylation of transcription factors, including CREB protein. Cross-
connections of these protein kinases with other signalling pathways exist in the cytoplasm, 
e.g. with PKA, mitogen activated protein kinases (MAPK), and Akt (PKB). Consequently, 
CaMK are connected to the processes related to neuroplasticity and neuronal protection 
against apoptosis (Berridge et al., 2000; Miyamoto, 2006; Soderling, 1999).  
Calcineurin dephosphorylates nuclear factor of activated T cells (NFAT), which afterwards 
enters into the nucleus and completes NFAT transcription complexes; these complexes 
regulate expression of growth factors, cytokines and other molecules essential for 
morphogenesis, development and function of neurons and other cells. Stimulus activating 
NFAT signalling pathway may originate from receptors with tyrosine kinase activity, ion 
channels, non-receptor tyrosine kinases, G protein-coupled receptors, and gap junctions 
(Wu et al., 2007). Other targets of calcium are adenylate cyclases (AC), some of them are 
activated others are inhibited. Further, Ca2+ stimulates some of cAMP phosphodiesterases 
(PDEs) resulting in changes of cAMP concentration; cAMP concentrations affect calcium 
levels through the activation of Ca2+-channels or pumps by protein kinase A (PKA).  
Activation of nitric oxide synthase (NOS) is an important role of Ca2+. NOS enables NO 
production, activation of sGC and cGMP production; the cGMP influences activity of Ca2+ 
channels and pumps (feedback). Phosphoinositide-3-kinase (PI3K) interferes in the calcium 
pathways through the production of phosphatidylinositol 3,4,5-trisphosphate (PIP3), which 
activates non-receptor tyrosine kinase Btk consequently activating PLCǄ1, and IP3 is 
produced. Increased Ca2+ concentrations also activate PLCǅ which increases IP3 
concentrations. Conversely, Ca2+ can decrease IP3 production by the activation of IP3-kinase 
(IP3K). Calcium activates tyrosine kinases enriched with proline (PYK2), which activate  
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AC – adenylate cyclase (adenylyl cyclase); BDNF – brain-derived neurotrophic factor; Btk – Bruton 
tyrosine kinase; CaM – calmodulin; CaMK – calcium and calmodulin-dependent protein kinase; cAMP – 
cyclic adenosine monophosphate; CBP – CREB binding protein; CREB protein – cAMP response element-
binding protein; cGMP – cyclic guanosine monophosphate; ER – endoplasmic reticulum; GPCR – G 
protein-coupled receptors; IP3 – inositol 1,4,5-trisphosphate; IP3K – IP3 kinase; IP3R – IP3 receptor; MAPK – 
mitogen-activated protein kinase; mCU – mitochondrial Ca2+ uniporter; NCX – Na+/Ca2+ exchanger; NFκB 
– nuclear factor κB; NFAT – nuclear factor of activated T cells; NO – nitric oxide; NOS – nitric oxide 
synthase; p300 – transcriptional co-activating protein; PDE – phosphodiesterase; PI3K – phosphoinositide 
3-kinase; PIP2 – phosphatidylinositol 4,5-bisphosphate; PIP3 – phosphatidylinositol 3,4,5-trisphosphate; 
PKA – protein kinase A, cAMP dependent protein kinase; PLC – phosphoinositide phospholipase C, 
phospholipase C; PMCA – plasma membrane Ca2+ ATPase; PYK2 – tyrosine kinase enriched with proline; 
ROC – receptor-operated channel; RyR – ryanodine receptor; VOC – voltage-operated channel;  - 
activation;  - inhibition 
Fig. 4. Calcium signalling pathway (Fišar & Hroudová, 2010). Detailed description in the text. 
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small GTPases Ras and mitogen-activated protein kinases (MAPKs). Protein kinases 
phosphorylate cellular proteins, which results in the cellular response to elevated Ca2+ 
concentrations, including induction of gene expression. 
3.5 Wnt pathway 
The Wnt signalling pathway activated by Wnt growth factors describes a complex of 
processes well known for their roles in embryogenesis and cancer, but also involved in 
normal physiological processes and in regulation of adult hippocampal neurogenesis 
(Clevers, 2006; Fuerer et al., 2008; Lie et al., 2005). Wnt signals are transmitted at least by 
three intracellular pathways; the most investigated one is canonical Wnt signalling pathway, 
which primarily modulates cellular processes during the cell development.  
The canonical Wnt pathway (Fig. 5) describes a series of events occurring when Wnt 
glycoproteins bind to transmembrane receptor of the Frizzled family (WntR); membrane  
 
APC – adenomatous polyposis coli; Bax – proapoptotic factor from Bcl-2 family; CBP – CREB binding 
protein; CK – casein kinase; ER – estrogen receptor; GSK-3ǃ – glycogen synthase kinase-3ǃ; LEF – 
lymphoid-enhancing factor; LRP 5/6 – transmembrane protein; TCF – T cell factor; WntR – Wnt 
receptor (transmembrane receptor of the Frizzled family);  - activation;   - inhibition 
Fig. 5. Canonical Wnt pathway (Fišar & Hroudová, 2010). Detailed description in the text. 
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protein LRP 5/6 phosphorylated by casein kinase 1Ǆ (CK1Ǆ) participates in the binding. 
Signal is transferred on the cytoplasmic protein Dishevelled that increases phosphorylation 
of glycogen synthase kinase-3ǃ (GSK-3ǃ). Therefore, complex of proteins that includes GSK-
3ǃ, axin, protein APC (adenomatous polyposis coli) and casein kinase 1ǂ (CK1ǂ) is 
inhibited, because phosphorylation of both of axin and ǃ-catenin (mediated by GSK-3ǃ) is 
decreased, and non-phosphorylated axin is degraded (Lee et al., 2003). It is suggested that 
heterotrimeric G proteins participate in disturbance of interaction GSK-3ǃ with axin; some 
of these G proteins are probably associated with WntR (Liu et al., 2005). If the GSK-3ǃ/axin 
complex is not inhibited, ǃ-catenin is phosphorylated by CK1ǂ and GSK-3ǃ and ǃ-catenin is 
degraded. If ǃ-catenin is not degraded, it accumulates in cytoplasm and is transported by 
importin into the nucleus. Main target of ǃ-catenin in the nucleus is transcription factor TCF 
(T cell factor) from LEF (lymphoid-enhancing factor) family; connection of TCF and ǃ-
catenin leads to activation of transcription factor. TCF, ǃ-catenin and other transcription 
cofactors, such as CREB binding protein (CBP), activates the transcription of target genes. ǃ-
catenin activated by Wnt pathway interacts also with estrogen receptor (ER) and other 
nuclear receptors. Inhibition of GSK-3ǃ links Wnt pathway also with apoptosis (through the 
activation of proapoptotic factor Bax from Bcl-2 family) and Alzheimer’s disease (through 
tau protein phosphorylation). Recently, this pathway has been linked to therapeutic effects 
of lithium administered at bipolar disorders, probably through the activation of 
transcription factors by ǃ-catenin. 
3.6 Tyrosine kinase pathway 
Tyrosine kinase pathway is activated by growth factors. Binding of neurotrophin to its trk 
receptor leads to three consequent processes (Fig. 6): 
1. Receptor’s autophosphorylation leads to phosphorylation of SHC protein, on which 
complex GRB2 (growth factor receptor bound protein-2)-SOS (son of sevenless protein) 
is attached to the membrane. SOS activates small G protein Ras and it attaches Raf 
kinase to the membrane. Activated Raf phosphorylates mitogen-activated protein 
kinase kinases MEK1, MEK2 or MEK5, and activated MEKs phosphorylate extracellular 
signal-regulated kinases (ERKs). G protein-coupled receptors are involved also in the 
ERK activation, namely by the activation of protein kinases PKA or PKC that activate 
Raf, consequently ERKs are activated. Activated ERK1 and ERK2 are transported into 
the nucleus and phosphorylate nuclear targets there, especially transcription factor Elk1 
and kinase RSK (ribosomal protein S6 kinase). RSK has a principal role in regulation of 
gene transcription, because of its phosphorylation of a range of various factors. 
Phosphorylated Elk1 interacts with SRF (serum response factor) transcription factor, 
and transcription is initiated after the binding of a relevant response element in the area 
of c-Fos promoter. Phosphorylated RSK enables CREB phosphorylation; it binds to 
CREB binding protein (CBP) and to SRF/Elk1 complex, which leads to c-Fos 
transcription. As a result, there is regulation of immune and inflammatory processes, 
and control of cell growth and apoptosis. ERK5 is phosphorylated and activated by 
MEK5 (kinase of MAP kinase). In the contrast to ERK1 and ERK2, ERK5 is activated 
only by neurotrophins. ERK5 is included in cell survival through the MEF2 (myocyte 
enhancer factor 2) substrate (Wada & Penninger, 2004). 
2. Phosphorylation of phospholipase CǄ (PLCǄ) by trk receptor enables catalysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) cleavage to diacylglycerol (DAG) and  
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Akt – protein kinase B (PKB); BAD – proapoptotic factor (Bcl-2-associated death promoter); BDNF – 
brain-derived neurotrophic factor; CaM – calmodulin; CaMK – calcium and calmodulin-dependent 
protein kinase; CBP – CREB binding protein; c-Fos – transcription factor; c-Jun – transcription factor; 
CREB protein – cAMP response element-binding protein; DAG – diacylglycerol; Elk1 – transcription 
factor; ERK – extracellular signal-regulated kinase; GSK-3ǃ – glycogen synthase kinase-3ǃ; IP3 – inositol 
1,4,5-trisphosphate; JNK – c-Jun N-terminal kinase (stress-activated protein kinase); MEF2 – myocyte 
enhancer factor 2; MEK – mitogen-activated protein kinase kinase; NFκB – nuclear factor κB; PDPK1 – 
3-phosphoinositide dependent protein kinase-1; PI3K – phosphoinositide 3-kinase; PIP2 – 
phosphatidylinositol 4,5-bisphosphate; PKA – protein kinase A; PKC – protein kinase C; PLC – 
phosphoinositide phospholipase C; Raf – protein kinase ; Ras – small GTPase; RSK – ribosomal protein 
S6 kinase; SHC – protein with SH2 domain; SOS – son of sevenless protein; SRF – serum response 
factor; trk – tropomyosin-related kinase;  - activation;   - inhibition 
Fig. 6. Tyrosin kinase pathway (Fišar & Hroudová, 2010). Detailed description in the text. 
inositol trisphosphate (IP3). DAG can activate phosphoinositide-3-kinase (PI3K) or 
various protein kinases C (PKCs). IP3 releases calcium from intracellular stores and it 
activates calmodulin (CaM) and Ca2+/CaM-dependent protein kinases (CaMKs).  
3. Phosphatidylinositol 3,4,5-trisphosphate (PIP3) is formed after the stimulation of PI3K 
heterodimers, which activates kinase PDPK1 (3-phosphoinositide dependent protein 
kinase-1) and therefore, protein kinase Akt (also known as PKB) is activated. Akt 
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supports survival and differentiation of neurons both by stimulation of transcription 
factors and by inhibition of proapoptotic factor BAD or glycogen synthase kinase-3ǃ 
(GSK-3ǃ). PI3Ks activate also PKC or they can indirectly activate protein kinases JNK 
(c-Jun N-terminal kinases), which are responsible for c-Jun phosphorylation and 
initiation of apoptosis (Cowan & Storey, 2003). 
4. Neuroplasticity 
Neuroplasticity is a fundamental mechanism of neuronal adaptation to environmental 
inputs. The term neuroplasticity (brain plasticity, cortical plasticity, cortical re-mapping) is 
used for description of either functional or structural changes of neurons and glial cells that 
occur in developing brain as well as in the adult brain in order to adjust to external or 
internal stimuli (Mesulam, 1999; Nestler et al., 2002). The most widely recognized forms of 
plasticity are learning, memory, and recovery from nervous system injury, which may 
happen through the change in the strength of connections among brain cells, by adding or 
removing connections, or by adding new cells.  
Neuroplasticity is linked to the concept of synaptic pruning (neuronal pruning, 
neurostructural reassembly), defined as regulatory processes, which facilitate a productive 
change in neural structure by reducing the overall number of neurons or connections, 
leaving more efficient synaptic configurations; really, excess of neurons was observed in the 
human newborn mediodorsal thalamus compared with that of the adult (Abitz et al., 2007). 
New findings suggest that all areas of the brain are plastic even after childhood. 
Neuroplasticity in the adult brain includes changes of dendritic functions, reorganization of 
synapses, long-term potentiation (LTP), long-term depression (LTD), branching and 
sprouting of axons and dendrites, synaptogenesis, and neurogenesis (Fišar & Hroudová, 
2010). Environmental changes could alter behaviour and cognition by adapting connections 
between neurons, and neurogenesis may be included in these processes. It is possible that 
there is a link between neurogenesis and learning-related changes in the brain. Adult 
neurogenesis in mammals is mainly restricted to the hippocampus and olfactory bulb; 
current research has revealed that other parts of the brain, the cerebellum included, may be 
also involved (Ponti et al., 2008). However, the reorganisation of the complex brain 
networks is not always beneficial for the individual. Maladaptive plasticity can be defined 
as behavioural loss or as development of disease symptoms resulting from plasticity 
changes in the adult brain (Draganski & May, 2008). 
The development of new synapses, the activity dependent changes in the strength of 
existing synapses and the elimination of synapses have been proposed to form basis of 
synaptic plasticity. The synaptic plasticity could be the cellular basis of certain forms of 
learning and memory (Citri & Malenka, 2008). Synaptic plasticity has been studied in many 
brain regions, the most frequently in the hippocampus. 
Recently, the concept was modified that synapse-specific forms of LTP and LTD at 
excitatory synapse can fully explain learning and experience-dependent plasticity. Intrinsic, 
inhibitory, and homeostatic plasticity were documented as additional forms of plasticity 
(Nelson & Turrigiano, 2008). A novel form of persistent synaptic plasticity was called 
metaplasticity (the plasticity of synaptic plasticity). Metaplasticity is induced by synaptic or 
cellular activity, but is not necessarily expressed as a change in the efficacy of normal 
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synaptic transmission. Instead, it is manifested as a change in the ability to induce 
subsequent synaptic plasticity, such as LTP or LTD. Thus, metaplasticity is a higher-order 
form of synaptic plasticity (Abraham & Bear, 1996). 
There is both postsynaptic and presynaptic plasticity. Postsynaptic plasticity involves 
changes in the number or sensitivity of postsynaptic receptors without any changes in the 
amount of neurotransmitter release. Basic mechanisms of postsynaptic plasticity are 
connected with activation of postsynaptic NMDA receptors followed by Ca2+ influx; 
calcium triggers following mechanisms contributing to synaptic plasticity in spines: 1. The 
regulation of channels and proteins involved in trafficking, cytoskeletal organization and 
protein synthesis; 2. Alterations of synaptic AMPA receptor properties, subunit 
composition and trafficking; 3. Actin reorganization and modulation of spine 
morphology; and 4. Initiation of local protein synthesis in spines and dendrites (Derkach 
et al., 2007).  
Presynaptic plasticity generally translates into an increase or a decrease of neurotransmitter 
release (García-Junco-Clemente et al., 2005). Presynaptic plasticity has the potential to 
greatly influence all of the neurotransmitters release sites within a given axon, such that 
changes in the output of one inhibitory interneuron could modify the activity of many of its 
downstream target neurons (Tóth & McBain, 2000). Mechanisms of presynaptic LTP or LTD 
may be independent on NMDA receptors. It is hypothesized that various forms of 
presynaptic plasticity can operate in a manner fundamentally distinct from most 
postsynaptic forms of plasticity (García-Junco-Clemente et al., 2005; McBain & Kauer, 2009). 
A new class of presynaptic plasticity that requires signalling by endocannabinoids has been 
identified in several brain structures (Chevaleyre et al., 2006). At many of these synapses 
presynaptically expressed forms of LTD can coexist with postsynaptic forms of LTD 
mediated by internalization of AMPA receptors (Nelson & Turrigiano, 2008). 
Learning and memory depend on long-lasting changes in synaptic strength. Long-term 
synaptic plasticity changes last from hours to weeks. These changes require induction of 
gene expression, production and insertion of new proteins. Activation of ǃ-adrenoceptors 
can enhance LTP and facilitate long-term memory storage. Cyclic AMP/PKA and 
extracellular signal-regulated protein kinase cascades are important to express the long-
lasting LTP in hippocampus, amygdala, and cortex (Pittenger & Duman, 2008). 
Transcription factor CREB is particularly important in modulation of synaptic plasticity. 
CREB is activated (phosphorylated) by PKA and other kinases upon synaptic stimulation 
during learning (Carlezon et al., 2005). 
5. Stress, HPA axis and glutamate neurotoxicity 
Stress may be defined as any environmental change, whether internal or external, that 
disturbs homeostasis (Leonard & Myint, 2009). Stress system is located in both the central 
nervous system and peripheral organs. Central functions of the stress response include 
facilitation of arousal, alertness, cognition, attention and aggression, inhibition of vegetative 
functions, and activation of counter-regulator feedback loops. Peripheral functions include 
increase of oxygenation, nutrition of the brain, hearth and skeletal muscles, increase of 
cardiovascular tone and respiration, increase of metabolism and detoxification, and 
activation of counter-regulatory feedback loops (Chrousos, 2009). 
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Stress activates both hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic 
nervous system. The main central effectors of stress system include corticotrophin-releasing 
factor (CRF), arginine vasopressin (AVP) and norepinephrine. Chronic stress, as a result of 
the hypersecretion of cortisol, causes a decrease in serotonin turnover partly as a 
consequence of increased metabolism of tryptophan (Leonard & Myint, 2009). Increased 
activity of the HPA axis has been reported not only after stress but also in pregnancy and in 
many diseases, such as Cushing syndrome, depression, anorexia nervosa, obsessive-
compulsive disorder, panic disorder, alcoholism, diabetes mellitus, metabolic syndrome, 
hyperthyroidism, etc. (Chrousos, 2009). 
Stressors provoke the secretion of epinephrine and norepinephrine by the sympathetic 
nervous system, to induce the flight-or-fight response, and of the glucocorticoids by the 
adrenal gland. Catecholamine action involves activation of ǃ-adrenoceptors and initiation of 
second messenger cascades in target cells within seconds; whereas, glucocorticoid’s effects 
can take hours to emerge, as they involve transcriptional events. Brain areas involved in the 
stress response include the prefrontal cortex, the hippocampus, and the amygdala; they 
undergo stress-induced remodelling, which alters behavioural and physiological responses 
(McEwen, 2007). Many central aspects of stress response are modulated, and in some cases 
mediated, by glutamate neurotransmission in the prefrontal cortex (Moghaddam, 2002). 
Stress and stress hormones produce both adaptive and maladaptive effects in the brain 
(McEwen, 2007). It is known that stress is important contributor to psychosocial and 
physical disorders. The relationship between stressful life events and development of mood 
disorders in vulnerable subjects has been long established (Aguilera et al., 2009; Caspi et al., 
2003; Johnson, 2005; Kendler et al., 1999). Adverse childhood experiences have been 
described as one of the major environmental risk factors for depressive disorder.  
Acute and chronic stress can have quite different effects on neuroplasticity. The mild stress 
for a few hours can enhance cognition by facilitating aspects of synaptic plasticity in the 
hippocampus; these effects are mediated by high-affinity corticosteroid receptors. In 
contrast, excessive glucocorticoid exposure in the hippocampus as a result of major and 
prolonged stress can be directly toxic to neurons, or can increase the neurotoxicity of various 
hippocampal insults (Lee et al., 2002; McEwen & Sapolsky, 1995; Sapolsky, 1996). 
Stress produces a rapid increase in glutamate efflux in the prefrontal cortex and the 
hippocampus (Moghaddam, 2002). An excess of glutamate in the synapse leads to excess of 
cytosolic calcium, which produce overactivity of calcium-dependent enzymes and it leads to 
cytoskeletal degradation, protein malformation and oxygen radical generation. These 
processes can lead to atrophy or death of neurons (Atlante et al., 2001; Lipton, 1999). 
Different insults, such as hypoxia-ischemia, seizure and hypoglycaemia, all of them activate 
this pathway. 
Neurons mobilize a variety of defences when are challenged with glutamatergic insults, e.g. 
removal of glutamate from the synapse, and of calcium from the cytoplasm, production of 
heat shock proteins (HSP), protective hyperpolarisation, and protective upregulation of 
antioxidant enzymes (Lee et al., 2002). The glia cells account for the majority of glutamate 
uptake. 
Processes accompanying neuroplasticity are extremely energy-consuming and interfere with 
different intracellular pathways included in signal transduction or in apoptosis. Thus, it 
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seems to be useful to study the mitochondrial dysfunctions in relation to neuroplasticity, 
mechanisms of stress response, pathophysiology of mood disorders, and mechanisms of 
action of psychotropic drugs, antidepressants and mood stabilizers included (Hroudová & 
Fišar, 2011). It was proposed that subtle deficits in the mitochondrial function likely play an 
important role in various facets of bipolar disorder, and that enhancing mitochondrial 
function may represent a critical component for the optimal treatment of the disorder 
(Quiroz et al., 2008). 
There are close relationships between the mechanisms of synaptic plasticity, effects of stress, 
mechanisms of antidepressant action, and pathophysiology of depression (Pittenger & 
Duman, 2008). In order to explain these relationships, interactions among signal 
transduction pathways have been studied (Fišar & Hroudová, 2010; Hroudová & Fišar, 
2011), including the role of mitochondria (Fig. 7). 
 
AA – arachidonic acid; ATP – adenosine-5'-triphosphate; Bax, Bak, BAD – proapoptotic factors of Bcl-2 
family; Bcl-2 – antiapoptotic factor of Bcl-2 family; BDNF – brain-derived neurotrophic factor; CaM – 
calmodulin; cAMP – cyclic adenosine monophosphate; CREB – cAMP response element-binding; m – 
potential on the inner mitochondrial membrane; EAAT – excitatory amino acid transporter; ER – 
endoplasmic reticulum; Glu – glutamate; MAO – monoamine oxidase; nNOS – neuronal nitric oxide 
synthase; NO – nitric oxide; PKA – protein kinase A; PLA2 – phospholipase A2; PLC – phospholipase C; 
ROS – reactive oxygen species; RONS – reactive oxygen and nitrogen species 
Fig. 7. Principal mechanisms of glutamate neurotoxicity (Hroudová & Fišar, 2011). Detailed 
description in the text. 
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Principal mechanisms leading to neuronal impairment and cell death are composed of  
1. Decreased adenosine triphosphate (ATP) production; 
2. Increased production of reactive oxygen and nitrogen species (RONS); 
3. Initiation of apoptotic processes; 
4. Impaired calcium homeostasis.  
Decrease of ATP production leads to impairment of ATP-dependent processes and therefore 
to changed cellular functions (Fig. 7). Insufficient function of Na+K+- ATPases leads to 
membrane depolarization. Membrane depolarization changes the functions of amino acids 
transporters and increases concentration of extracellular glutamate. Voltage-gated ion 
channels (VOC) and/or ligand-dependent calcium channels (ROC) are activated and 
mediate calcium influx. Intracellular calcium causes functional changes of amino acid 
transporters, enhances extracellular glutamate and extends neurotoxicity. Increased levels of 
synaptic glutamate can be mediated also by release of glutamate from astrocytes. The 
activation of ionotropic glutamate receptors leads to higher calcium influx into the cell, 
which is followed by increased activation of phospholipases, proteases, and endonucleases. 
For example, activation of phospholipase A2 (PLA2) by calcium releases membrane 
arachidonic acid (AA), which induces production of superoxide.  
High intracellular calcium levels induce overload of mitochondrial calcium, leading to 
increase of reactive oxygen species (ROS) production and inhibition of ATP production. 
Activation of calcium-dependent protein phosphatases (e.g. calcineurin) causes 
translocation of proapoptotic factor BAD into the mitochondria and triggers apoptosis by 
sequestration of antiapoptotic factors Bcl-2 and Bcl-xL. Release of cytochrome c (cyt c) and 
other proapoptotic factors from the intermembrane space of mitochondria induces the 
formation of apoptosome, and consequently triggers activation of caspases and apoptosis. 
Apoptosis-inducing factor (AIF) is another factor released by mitochondria. Mitochondria in 
the brain are also a target of nitric oxide (NO) action. 
6. Mechanisms of action of antidepressants and mood stabilizers 
Current antidepressant medications are effective in about 60% of treated patients (Nelson, 
1999; Papakostas et al., 2007) and significant therapeutic response is observed after several 
weeks of treatment. Thus, faster and more effective pharmacological treatments for 
depressive disorders are greatly needed. 
Biochemical effects of antidepressants and mood stabilizers are studied with the aim to 
discover both molecular mechanism of their therapeutic efficiency and neurochemical 
nature of mood disorders. Both complex clinical pattern of mood disorders and adaptive 
changes in activity or availability of a large number of components of signalling pathways 
after long-term treatment with antidepressants is responsible for the fact, that definite 
molecular mechanisms responsible for therapeutic action of drugs are not known.  
It seems that psychotropic drugs used in the therapy of mood disorders show neurotrophic 
or neuroprotective effects after long-term treatment. Thus, next to adenylate cyclase, 
guanylate cyclase, phosphoinositide and calcium systems, attention has been paid to 
tyrosine kinase pathway, Wnt pathway and inflammatory pathway. 
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6.1 Antidepressants 
Antidepressants are psychiatric medication used to treatment of mood disorders, such as 
major depression, dysthymia, and anxiety disorders. Easily 41 drugs are currently used as 
antidepressants worldwide and many other drugs are administered as supportive therapy 
or holding course. At the level of chemical synapses, antidepressants usually act as 
serotonin or norepinephrine reuptake inhibitors, as inhibitors of the degradation of 
monoamine neurotransmitters, or as agonists or antagonists of their receptors. Therefore, 
the administration of antidepressants induces increased concentrations of norepinephrine 
and serotonin in the synaptic cleft. Consequently, increased activation or inhibition occurs in 
processes of intracellular signalling pathways, mainly in adenylate cyclase and 
phosphoinositide pathway. 
Clinical effects of antidepressants are obviously caused by their ability to induce adaptive 
changes in neurotransmission, mainly serotonergic and noradrenergic. Changes in the 
availability of neurotransmitters and also in the density and sensitivity of their receptors 
and transporters are not sufficient to explain origin and course of the mood disorders 
neither the mechanisms of action of antidepressants and mood stabilizers. It was supposed 
that intracellular processes included in apoptotic, neurodegenerative, and inflammatory 
pathways are responsible for final therapeutic effects (Porcelli et al., 2011).  
Antidepressants are currently classified according to their direct biochemical effects, which 
are well known in comparison with their long-term effects. The first antidepressants were 
monoamine oxidase inhibitors (MAOIs) and nonselective serotonin and/or norepinephrine 
reuptake inhibitors referred to as tricyclic antidepressants (TCAs). MAOIs act as 
antidepressants by blocking of enzyme that degrades monoamine neurotransmitters; TCAs 
act as antidepressants by blocking membrane transporters ensuring reuptake of 5-HT or NE, 
thus cause increased extracellular neurotransmitter concentrations. Next generations of 
antidepressants include selective serotonin reuptake inhibitors (SSRIs), norepinephrine 
reuptake inhibitors (NRIs), serotonin-norepinephrine reuptake inhibitors (SNRI), 
noradrenergic and specific serotonergic antidepressants (NaSSAs), serotonin antagonist and 
reuptake inhibitors (SARIs), norepinephrine-dopamine reuptake inhibitors (NDRIs), 
melatonin receptors agonist and selective serotonin antagonist (MASSA), sigma receptors 
agonist, and drugs directly affecting the neuroplasticity renewal. However, other classes of 
antidepressants may be suggested; e.g. antagonists of 5-HT2C receptors may be classified as 
norepinephrine-dopamine disinhibitors (NDDIs), because they act by antagonizing 
receptors that normally acts to inhibit norepinephrine and dopamine release. Tianeptin was 
initially classified as selective serotonin reuptake enhancer (SSRE); however, its affinity to 
serotonin transporter is low and it was supposed that its therapeutic action is related to 
restore normal neuroplasticity in circumscribed limbic brain regions and to reverse stress-
induced impairments in synaptic glutamate transmission (McEwen et al., 2010). It is of 
interest that new psychotropic drugs are multifunctional, i.e. agents with more than one 
putative therapeutic mechanism of action (Stahl, 2009). 
6.1.1 Effect on glutamate system 
Antidepressants affect learning and memory in animal models and enhance structural 
plasticity and hippocampal neurogenesis (Drzyzga et al., 2009; Kasper & McEwen, 2008; 
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Warner-Schmidt & Duman, 2006). Antidepressants can directly modulate glutamatergic 
neurotransmission through NMDA or AMPA receptors; it is likely that an intimate 
relationship exists between regulation of monoaminergic and glutamatergic 
neurotransmission and antidepressant effects (Paul & Skolnick, 2003). As mentioned 
above, tianeptine prevents or reverses stress-associated structural and cellular changes in 
the brain and normalizes disrupted glutamatergic neurotransmission in the hippocampus, 
the amygdala, and the cortex (Kasper & McEwen, 2008; McEwen et al., 2010). An 
inhibition of an excessive release of glutamate appears to be important for mechanisms of 
action of lamotrigine and riluzole (Zarate et al., 2006a). Robust and rapid antidepressant 
effect on individuals with treatment-resistant depression resulted from a single 
intravenous dose of ketamine (a non-competitive NMDA receptor antagonist and 
psychomimetic) (Diazgranados et al., 2010; Zarate et al., 2006b). These effects suggest that 
depressive symptoms can be improved by altering the action of glutamate (Krishnan & 
Nestler, 2008). 
6.1.2 Effect on neuroplasticity and neurogenesis 
Time-dependent therapeutic effects of antidepressants could be related to changes in gene 
expression in the brain. If a deficit in neuroplasticity is included in pathophysiology of 
depression, then it can be supposed that effects of stress on the mechanisms of 
neuroplasticity contribute to the genesis of depression and long-term antidepressant 
treatment affects the same mechanisms (Pittenger & Duman, 2008).  
There are many evidences that antidepressants increase signalling pathways related to 
neuroplasticity by upregulation of cAMP/PKA/CREB cascade, by regulation of CaMKII 
activity and by upregulation of the MAPK cascade. The hypothesis that long-term 
antidepressant treatment enhances neuroplasticity is based on upregulation of expression of 
many neurotrophic factors, especially of BDNF, in the hippocampus and the prefrontal 
cortex (Bocchio-Chiavetto et al., 2006; Duman & Monteggia, 2006; Nibuya et al., 1996; 
Pittenger & Duman, 2008). 
A neurotrophic model for the molecular mechanism of action of antidepressant treatments 
includes following steps: 1. Antidepressant treatment causes direct inhibition of serotonin 
and/or norepinephrine reuptake or breakdown, which is followed by elevation of 
extracellular levels of serotonin and/or norepinephrine; 2. Long-term treatment causes 
adaptive changes in the function and expression of serotonin and norepinephrine receptors, 
increase in the cAMP signal transduction and increase in expression of the transcription 
factor CREB; 3. Increased activity of the cAMP signal transduction cascade induces 
increased expression of BDNF and its receptor trkB; thus, neuroplasticity is improved and 
neuron survival and recovery is increased. 
The results support the hypothesis that treatment by antidepressant lead to effects similar to 
neurotrophic. One of the target genes of pharmacotherapy is BDNF gene. BDNF supports 
processes implicated in neuronal plasticity and in renewal or improvement of neuronal 
connectivity. The renewal of synaptic connections and signalling pathways enables the 
normal function of neurotransmitters. It is suggested, that antidepressants can eliminate 
stress effects on the hippocampus and improve the symptoms of depression in this way. 
Due to the complexity of intracellular processes it is relatively difficult to establish this 
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hypothesis. There is not large longitudinal study that might prove the ability of 
antidepressants to reverse atrophy of brain structures and prevent it. 
The chronic administration of antidepressants also increases neurogenesis in hippocampal 
structures, i.e. it increases proliferation and survival of new neurons. Reverse effects of 
stress and antidepressant on the hippocampal neurogenesis indicate that changes in 
hippocampal neurogenesis can be significant in clinic syndrome of depression, although it is 
a complex disorder that targets more than one region of the brain. Coupling of hippocampal 
neurogenesis to pathophysiology of depression requires further research to be confirmed 
(Gass & Riva, 2007; Santarelli et al., 2003). 
6.1.3 Effect on inflammatory pathway 
Suggestion that the activation of immune responses and the release of inflammatory 
cytokines (including IL-1ǃ, IL-6, TNF-ǂ) may play a role in the pathophysiology of 
depression is supported by observation that there is association between antidepressant 
action and cytokine functioning. The most consistent finding has been that antidepressant 
treatment significantly reduces interleukin-6 (IL-6) plasma concentrations, which are 
elevated in depression (Janssen et al., 2010). Proposed mechanisms for the antidepressant 
effects on cytokine function include: 1. Increase of intracellular cAMP/PKA pathway by 
antidepressants leads to inhibition of NFκB, a transcription factor which promote 
proinflammatory gene expression; 2. Antidepressants and glucocorticoids may act via 
common intracellular signalling pathways; e.g. activated PKA is able to enhance 
glucocorticoid receptor-DNA binding (Pace & Miller, 2009); 3. Increased extracellular levels 
of serotonin after treatment with serotonergic antidepressants exhibit immunosuppressive 
effects (Kubera et al., 2000), and depleted intracellular 5-HT levels reduce cytokine levels 
through inhibition of mRNA expression (Maes, 2001); 4. Antidepressants may reverse effect 
of cytokines on depression of hippocampal neurogenesis (Koo & Duman, 2008). In 
conclusion, the inflammatory and neurodegenerative pathways might provide new targets 
for antidepressant development (Catena-Dell’Osso et al., 2011). 
6.1.4 Direct, early and long-term effects 
Sequence of biochemical events induced by antidepressants is crucial for discovery of 
molecular mechanisms associated with their therapeutic effects. Direct (immediate) 
biochemical effects of antidepressants leading to their therapeutic action include: 
1. Inhibition of reuptake of monoamine neurotransmitters, i.e. inhibition of membrane 
transporters for serotonin, norepinephrine or dopamine. 
2. Inhibition of metabolism of monoamine neurotransmitters, i.e. monoamine oxidase 
inhibition, 
3. Receptor activation, e.g. postsynaptic serotonin receptors type 1A (5-HT1A) or sigma 
receptors. 
4. Blockade (antagonism) of monoamine receptors, e.g. postsynaptic serotonin receptors 
type 2A and 2C (5-HT2A, 5-HT2C) and presynaptic ǂ2-adrenoceptors. 
5. Inhibition or activation of several intracellular components of signalling pathways 
participant in neurotransmission. 
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Neurochemical events for antidepressant action classified into direct (immediate) effects, 
early (intermediate) effects, and long-term (delayed) effects are summarized in Fig. 8. 
 
Fig. 8. Sequence of effects of antidepressants 
Immediate biochemical effects of antidepressants are followed by early events, such as 
increasing of availability and extracellular levels of monoamine neurotransmitters, increasing 
of monoamine receptors activation, activation of intracellular signalling pathways, activation 
of transcription factors and increasing of gene expression of neurotrophic factors.  
It is evident that adaptive changes in central neurotransmission are responsible for 
therapeutic effects of antidepressants. These adaptive processes and their regulatory 
mechanisms are studied on the neurochemical, neuroimmune, neuroendocrine, 
chronobiological, and genetic level primarily: 
1. Neurochemical events include a) changes of neurotransmitter receptor density and 
sensitivity, which were not confirmed for in vivo treatment with many antidepressants 
and mood stabilizers on patients with affective disorders (Nikolaus et al., 2009; 
Richelson, 2003); b) antiapoptotic effects and changes in gene expression, 
neuroplasticity and neurogenesis, when stress-induced or depression-induced damage 
of brain cell functions and their interconnections are recovered after long-term 
treatment with antidepressants (Duman, 2009). 
2. Neuroimmune approach is based on observations that a) major depressive disorder is 
an inflammatory disorder with an overproduction of proinflammatory cytokines (Maes 
et al., 2009); b) anti-inflammatory effects of antidepressants participate on their 
pharmacological effects (Janssen et al., 2010). 
3. Neuroendocrine hypotheses suppose that therapeutic effects of antidepressants consist in 
regulation of HPA axis, which can be overactivated during depression (Nikisch, 2009). 
4. Chronobiological hypotheses connect therapeutic effects of antidepressants with 
synchronization of biological rhythms disturbed in depression (Bunney & Potkin, 2008; 
Mendlewicz, 2009; Schulz & Steimer, 2009). 
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5. Genetic factors contribute for about 50% of the antidepressant response (Crisafulli et al., 
2011). Epigenetic changes are studied both in relation to gene-environment interactions 
(G  E) (Caspi et al., 2003; Uher, 2008) and in animal models of stress, depression and 
antidepressant treatment (Schroeder et al., 2007; Tsankova et al., 2007; Yasuda et al., 
2009).  
6.2 Mood stabilizers 
Mood stabilizers are psychiatric medication used in treatment of mood disorders, which are 
characterized by intense and sustained mood shifts (e.g. bipolar disorder). Most of mood 
stabilizers are anticonvulsants (valproate, carbamazepine, and lamotrigine), with an 
important exception of lithium, which is the oldest and the best known mood stabilizing 
drug. Some atypical antipsychotics (olanzapine, quetiapine, aripiprazole, risperidone, 
ziprasidone) have mood stabilizing effects, as well. It is also suggested that ǚ-3 fatty acids 
may have a mood stabilizing effect. It is hypothesized that ǚ-3 fatty acid deficiency may 
contribute to elevated phosphoinositide-PKC in neuropsychiatric illness (schizophrenia, 
bipolar disorder, major depressive disorder), because ǚ-3 fatty acids act as endogenous 
inhibitors of second messenger-regulated protein kinases (PKA, PKC, CaMK, MAPK) 
(McNamara et al., 2006; Mirnikjoo et al., 2001). 
Mood stabilizers affect multiple sites in intracellular signalling pathways (Fig. 9). Main 
targets of mood stabilizers are neurotrophin BDNF, ERK pathway, and pathways 
modulated by GSK-3 or Bcl-2 (Einat & Manji, 2006; Gould & Manji, 2005; Shaltiel et al., 
2007). Molecular and cellular targets of mood stabilizers include enzymes inhibited by 
lithium (inositol monophosphatase, inositol polyphosphate 1-phosphatase, GSK-3, fructose 
1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), enzymes inhibited 
by valproate (succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, 
histone deacetylase), targets of carbamazepine (sodium channels, adenosine receptors, 
adenylate cyclase), and components of signalling pathways regulated by multiple drugs 
(PKC, cAMP, arachidonic acid) (Gould et al., 2004). Furthermore, lithium and valproate 
reduce transport of myo-inositol into the cells, which leads to reduced PKC activity. Lithium 
and valproate increase Bcl-2 concentrations (Chen et al., 1999) and inhibit GSK-3 activity 
(lithium directly, valproate indirectly). Valproate activates MAPK signalling pathway and 
regulates stress proteins of endoplasmic reticulum (Bown et al., 2002). Through the effects 
on Bcl-2 and p53 (proapoptotic protein), lithium affects mitochondria by stabilization of 
membrane integrity and prevention of mitochondrial membrane permeability transition 
pores (MPTPs) opening; i.e. by regulating the key process in cell death leading to at least 
temporary loss of ΔǙm, input of water into matrix and equilibration of ions concentrations. 
Both lithium and valproate have neuroprotective effects based on protection from 
glutamatergic neurotoxicity by inactivation of NMDA receptors, on activation of cell 
survival factors such as phosphoinositide 3-kinase/protein kinase B pathway, and on 
induction of neurotrophic and neuroprotective proteins. Lithium protects against DNA 
damage, caspases activation, and apoptosis of neurons (Chuang, 2005). Increased 
concentrations of N-acetyl aspartate (NAA, marker of neuronal viability and 
functionality) in grey matter after the chronic lithium administration support its strong 
neuroprotective and neurotrophic effects in humans. Lithium also increases hippocampal 
neurogenesis. 
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AC – adenylate cyclase (adenylyl cyclase); Akt – protein kinase B (PKB); BAD – proapoptotic factor (Bcl-
2-associated death promoter); Bcl-2 – antiapoptotic factor of Bcl-2 (B-cell CLL/lymphoma 2) family; 
BDNF – brain-derived neurotrophic factor; CaM – calmodulin; CaMK – calcium and calmodulin-
dependent protein kinase; cAMP – cyclic adenosine monophosphate; CREB protein – cAMP response 
element-binding protein; DAG – diacylglycerol; ERK – extracellular signal-regulated kinase; GluR – 
ionotropic glutamate receptor; GPCR – G protein-coupled receptors; GSK-3 – glycogen synthase kinase-
3; I – inositol; IP – inositol monophosphate; IP2 – inositol bisphosphate; IP3 – inositol trisphosphate; 
MAPK – mitogen-activated protein kinase; MARCKS – myristoylated alanine-rich C-kinase substrate; 
MEK – mitogen-activated protein kinase kinase; MPTP – mitochondrial membrane permeability 
transition pore; PI3K – phosphoinositide 3-kinase; PIP2 – phosphatidylinositol 4,5-bisphosphate; PKA – 
protein kinase A; PKC – protein kinase C; PLC – phosphoinositide phospholipase C; Raf – protein 
kinase ; Ras – small GTPase; RSK – ribosomal protein S6 kinase; trkB – neurotrophic tyrosine kinase, 
receptor, type 2; VPA – valproic acid; WntR – Wnt receptor (transmembrane receptor of the Frizzled 
family);  - activation;   - inhibition 
Fig. 9. Neurotrophic and neuroprotective effects of antidepressants and mood stabilizers. 
Detailed description in the text. 
7. Advances in neurochemical hypotheses of mood disorders 
There are many hypotheses of mood disorders; however, current clinical, neurochemical, 
neurophysiological, genetic, and neuroimaging data are not sufficient for enunciation of 
theory of mood disorder. Thus, the ethiopathogenesis of major depressive disorder and 
other mood disorders is still unclear. 
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The neurochemical hypotheses of mood disorders were developed from neurotransmitter 
hypotheses to receptor and postreceptor hypotheses. Inadvertently induced depression by 
reserpine and effectiveness of first antidepressants from the class of TCA or MAOI led to the 
hypothesis that affective disorders are due to catecholamine and/or indolamine deficiency in 
the CNS (Coppen, 1967; Schildkraut, 1965). Single deficit of monoaminergic neurotransmission 
is insufficient to elucidation of neurochemistry of mood disorders. It was deduced that 
disposition of CNS characterized by disturbance in function of receptors for the key 
monoamine neurotransmitters is determining factor. Receptor malfunction may be caused by 
depletion of monoamine neurotransmitters, by abnormalities in the receptor density and 
sensitivity, or by problems with signal transduction on postreceptor level. It was formulated a 
large amount of receptor hypotheses. Classical norepinephrine receptor hypothesis of affective 
disorders supposed increased density of postsynaptic -AR in depression (Banerjee et al., 1977; 
Vetulani & Sulser, 1975). Very elegant, although unconfirmed, was receptor catecholamine 
hypothesis (Richelson, 1990) that supposes that supersensitivity of catecholamine receptors in 
the presence of low levels of serotonin is the biochemical basis of depression. According to 
receptor hypotheses the common final result of chronic treatment by majority of 
antidepressants is the down-regulation or up-regulation of postsynaptic or presynaptic 
receptors. The delay of clinical response corresponds with these receptor alterations. However, 
problems in interpretation of molecular mechanisms of action of mood stabilizers and the 
introduction of new, more selective antidepressants led to new reflection upon the 
mechanisms of their action and to new neurochemical hypotheses. The most promising are 
recent investigations of the signalling pathways ensuring signal transduction.  
Introduction of newer antidepressants sustained the monoamine deficiency hypothesis and 
the monoaminergic signalling pathways continues to be one of the key targets of new 
antidepressants. For decades, research focused mainly on the role of monoamines in mood 
disorders. However, data are inconclusive and the monoamine hypothesis seems to be 
insufficient to explain depression (Catena-Dell’Osso et al., 2011). E.g., in vivo neuroimaging 
studies on human brain neurotransmission provide little evidence about deficits in 
monoaminergic neurotransmission. Reports on positron emission tomography (PET) or 
single-photon emission computed tomography (SPECT) of neurotransmission in depressive 
disorders showed that there is usually no reliable relationship between the binding potential 
of the neuroreceptor or transporter and the clinical condition of depressed subject (Nikolaus 
et al., 2009; Smith & Jakobsen, 2009). 
While dysfunctions within monoaminergic neurotransmitter systems are likely to play an 
important role in pathophysiology of mood disorders, it probably represents the downstream 
effects of more primary abnormalities in signal transduction. Thus, new theories about the 
pathophysiology of depression and the action of antidepressant treatment proposes that mood 
disorders are caused by structural or functional changes in particular molecules and signalling 
pathways in the brain, and that antidepressants function by counteracting these molecular 
changes. Neurodegeneration or impaired neurogenesis may be important mechanism of 
depression, and neurotrophins are key regulators of neurogenesis and neuroplasticity. 
Recovery of brain networks through increase of neuroplasticity induces antidepressant effect. 
It is supposed that structural and functional brain abnormalities in patients with depressive 
disorder may be associated with low levels of BDNF, abnormal function of hypothalamic-
pituitary-adrenal (HPA) axis and glutamatergic toxicity (aan het Rot et al., 2009; Krishnan & 
Nestler, 2008; Mathew et al., 2008).  
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Research on the biological basis of mood disorders emphasises the changes of neural 
networks and synaptic plasticity. Evidence exists for impairment of neuroplasticity in major 
depression. Chronic stress is known to contribute both to development of major depression 
in vulnerable persons and to reduction of synaptic plasticity, induction of structural changes 
in dendrites, and impairment of neurogenesis (Pittenger & Duman, 2008). Mitochondria 
may be primary regulators of these processes, as they regulate not only neuronal survival 
and death, but also plasticity. There is a mounting evidence for the role of mitochondrial 
dysfunction in the pathophysiology and treatment of bipolar disorder (Quiroz et al., 2008). 
Attention is paid also to changes in inflammatory pathways, because monoaminergic 
systems, cellular energetics and inflammation are interrelated in many complex manners 
(Gardner & Boles, 2011). 
7.1 Monoamine hypothesis 
Classic monoamine hypothesis of depression proposed that depression might be produced 
by a serotonin or norepinephrine deficiency at functionally important receptor sites in the 
brain, i.e. that brain monoamine systems have a primary direct role in depression. 
Nevertheless, the monoamine hypothesis of depression in itself could neither explain the 
whole mechanism of action of antidepressants, nor could it provide an explanation for how 
monoamine loss occurs (Nestler et al., 2002). According to advanced monoamine theory 
(Meyer et al., 2006), serotonin or norepinephrine levels in the brain are regulated by 
monoamine oxidase type A (MAO-A) activity mainly, and severity of symptoms of 
depression is related to changes in the activity of monoamine transporters in specific brain 
regions. Thus, both MAO-A activity and density of transporters are included in the 
pathophysiology of affective disorders. The advanced monoamine hypothesis was 
supported by observation that during a major depressive episode, both MAO-A density is 
elevated, resulting in greater metabolism of monoamines in the brain (Meyer et al., 2009), 
and brain SERT binding is diminished (Selvaraj et al., 2011). 
In order to test monoamine hypothesis, a series of studies was conducted to evaluate effects 
of monoamine depletion on depressive symptoms in depressed patients and in healthy 
controls. Relapse after serotonin depletion or catecholamine depletion was found to be 
specific to the type of antidepressant treatment and type of depletion. Serotonin or 
norepinephrine/dopamine depletion did not decrease mood in healthy controls and slightly 
lowered mood in healthy controls with a family history of major depressive disorder. In 
drug-free patients with major depressive disorder in remission, a moderate mood decrease 
was found for acute tryptophan depletion only. However, acute tryptophan depletion 
induced relapse in patients in remission who used serotonergic antidepressants (Delgado et 
al., 1999). Depletion studies failed to demonstrate a causal relation between serotonin and 
norepinephrine with depressive disorder (Cowen, 2008; Ruhé et al., 2007). The effects of 
acute tryptophan depletion on cognition in non-vulnerable participants are independent of 
mood changes (Mendelsohn et al., 2009). Even simultaneous disruption of serotonin and 
catecholamine systems didn’t significantly alter mood in unmedicated depressed subjects 
(Berman et al., 2002). These findings forced a major revision of the classic monoamine 
hypothesis of depression. According to this revised monoamine theory of depression (aan 
het Rot et al., 2009; Heninger et al., 1996) monoamine systems are only modulating other 
brain neurobiological systems that have more primary role in depression. 
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7.2 Neurotrophic, neuroplasticity and neurogenesis hypotheses 
The neurotrophic hypothesis of depression (Duman et al., 1997; Duman, 2002; Zarate et al., 
2006a; Einat & Manji, 2006) supposed that vulnerability to depression can arise as a result of 
neuronal damage (Table 1), e.g. after chronic stress, long-term increased levels of 
glucocorticoids, hypoglycemia, ischemia, certain viral infections, effects of neurotoxins, etc. 
The therapeutic effects of antidepressants consist of increased function of the noradrenergic 
or serotonergic system. It leads to increased activity of transcription factor CREB, higher 
expression of neurotrophin BDNF and its receptor trkB, and consequently to increased 
neuronal plasticity and resumption of cellular functions. 
 
Stimuli Mechanisms 
Chronic stress 
Hypoglycemia 
Ischemia 
Neurotoxins  
Viral infections 
Ǆ-radiation, UV 
Disturbed energetic metabolism 
Lack of growth factors 
Excitotoxicity  
Oxidative stress 
Necrotic and apoptotic processes 
Inflammatory processes 
Table 1. Stimuli and mechanisms of neuron damage, which could be related to vulnerability 
to depression 
Series of studies support the hypothesis that a reduction of BDNF could contribute to 
depression and that antidepressants mediate their therapeutic benefit by increasing levels of 
this factor in the hippocampus. A polymorphism in the BDNF gene has been associated with 
depression and bipolar disorder. BDNF levels have been found to be reduced in post-
mortem brain samples and in the blood of depressed patients, and these reductions are 
reversible by successful antidepressant treatment (Castrén et al., 2007; Castrén & Rantamäki, 
2008). In addition, the regulation of other growth factors may also play a role in the 
pathophysiology and the treatment of depression (Duman & Monteggia, 2006). Stress 
produces a sustained suppression of BDNF transcription through histone methylation, 
whereas antidepressants restore BDNF synthesis through histone acetylation (Tsankova et 
al., 2006). This suggests that chronic stress can cause long-lasting epigenetic changes that 
might be related to increased vulnerability to depression. 
Local infusions of BDNF into specific brain regions showed to mimic antidepressant effects 
in behavioural models of depression. However, the loss of BDNF and signalling through the 
trkB receptor in broad forebrain regions per se is not sufficient to mediate depression-like 
behaviour (Duman & Monteggia, 2006). BDNF does not produce uniform effects throughout 
the brain. Infusion of BDNF into the ventral tegmental area might be related to the 
development of a depression-like phenotype; therefore, the role of BDNF in the ventral 
tegmental area – nucleus accumbens (VTA-NAc) pathway is opposite to the role of BDNF in 
the hippocampus (Eisch et al., 2003). It is hypothesized that BDNF signalling in the VTA-
NAc is required for the establishment of associations with negative emotional stimuli; and 
under pathological conditions this signalling may establish abnormal associations leading to 
certain symptoms of depression (Nestler & Carlezon, 2006). 
The neurogenesis (neurogenic) hypothesis of depression (Jacobs, 2002) proposes that 
depression may develop due to the decreased neurogenesis in hippocampus and 
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antidepressants takes effect through the stimulation of neurogenesis. The first component of 
this hypothesis is not tenable, and the evidence for second component is conflicting 
(Sapolsky, 2004). 
Behavioural data support the hypothesis that regulation of neuronal plasticity might play an 
important role in expression of symptoms of bipolar disorder. Major intracellular signalling 
pathways in bipolar disorder and neural plasticity include protein kinase C (PKC) and 
extracellular signal regulated kinase (ERK) cascades, glucocorticoid receptor modulation, 
glycogen synthase kinase-3 (GSK-3), and antiapoptotic Bcl-2 (B-cell CLL/lymphoma 2), 
AMPA (ǂ-amino-3-hydroxyl-5-methyl-4-isoxazole propionic acid) receptors, and inositol 
homeostasis (Einat & Manji, 2006). The neuroplasticity hypothesis of depressive disorder 
(Pittenger & Duman, 2008) suggests that impaired mechanisms of neuroplasticity are core 
pathophysiological feature of the disorder, where chronic stress is an important causal factor 
in the development of this impairment, and where long-term treatment with 
antidepressants leads to modulation of impaired mechanisms of neuroplasticity. However, 
alterations in neuroplasticity do not produce the same effects in different brain regions.  
Hypothesis of cellular plasticity (Kempermann & Kronenberg, 2003) relates the 
neurotrophic and the neurogenic hypothesis in the statement that depression can be 
generally caused by damaged cellular plasticity leading to inadequate relations between 
structure and function.  
Molecular mechanisms leading to a disturbance of neuroplasticity are not known 
sufficiently. The bioenergetic and neurochemical model of bipolar disorder attempts to 
identify these mechanisms and focuses attention on mitochondrial dysfunctions (Kato & 
Kato, 2000; Stork & Renshaw, 2005). 
7.3 Network hypothesis 
According to the network hypothesis of depression, changes in levels of neurotrophins may 
not directly produce depression or an antidepressant effect, but neurotrophins may act as 
critical tools in the process whereby environmental conditions guide neuronal networks to 
better adapt to the environment (Castrén & Rantamäki, 2010). 
The network hypothesis (Castrén, 2005) proposes that mood disorders reflect problems in 
information processing within particular neural networks in the brain; antidepressant drugs 
and other treatments, which alleviate depression, function by gradually improving 
information processing within these networks. Therefore, disorders of the nervous system, 
including depression, might represent disturbances in the activity-dependent information 
processing of the brain, rather than in the chemical balance of signalling molecules. 
However, some observations seem to be incompatible with the network hypothesis, e.g. 
rapid relapse of depressive symptoms in some patients, circadian variations in mood, and 
the effect of sleep deprivation on improvement of the mood of patients with depression. 
These rapid effects on mood can not be accounted for a gradual change in the structure of 
mood influencing neural networks. 
The network hypothesis emphasizes the importance of processing of environmental 
information (such as social communication) in the recovery of the brain functions during 
treatment of mood disorders; so, treatment with psychotropic drug in itself is insufficient. 
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Findings that psychotherapy result in detectable changes in the brain (Etkin et al., 2005) and 
that combined use of psychotherapy and medication can lead to better treatment outcomes 
than the use of either mode of therapy alone (Elkin et al., 1989) are consistent with the 
network hypothesis. 
7.4 Inflammatory and neurodegenerative hypothesis 
The central nervous system, endocrine and immune systems use neurotransmitters, 
cytokines and hormones to communicate among them (Haddad et al., 2002). Now there is 
evidence that the activation of the immune system is associated with the symptoms of 
depression (Leonard & Myint, 2009; Catena-Dell’Osso et al., 2011). The inflammatory and 
neurodegenerative hypothesis of depression (Maes et al., 2009) supposes that depression is 
associated with both inflammatory processes, as well as with neurodegeneration and 
reduced neurogenesis. According to this hypothesis, enhanced neurodegeneration and 
impaired neurogenesis in depression are caused by inflammatory processes, related to the 
production of oxidative and nitrosative stress, tryptophan catabolites along the 
indoleamine-2,3-dioxygenase pathway, proinflammatory cytokines and lowered ǚ-3 
polyunsaturated fatty acid status. Anti-inflammatory compounds should be able to 
counteract at least partly the enhanced neurodegeneration and decreased neurogenesis. 
7.5 Mitochondrial dysfunction hypothesis 
While dysfunctions within monoaminergic neurotransmitter systems are likely to play an 
important role in pathophysiology of mood disorders, it probably represents the 
downstream effects of more primary abnormalities in signal transduction. New theories 
about the pathophysiology of depression and mechanisms of action of antidepressants 
proposes that regulation of intracellular signalling pathways manifested by disturbed 
neuroplasticity plays a critical role in higher-order brain functions. Mitochondria may be 
primary regulators of these processes. It is supposed that mitochondrial dysfunctions are 
included in pathophysiology of mood disorders. Disturbances in activity of mitochondrial 
enzymes, effects of intracellular calcium and energy metabolism, damage of mitochondrial 
DNA, and action of psychotropics on mitochondria were observed in many 
neuropsychiatric illnesses, mood disorders included.  
Subtle deficits in mitochondrial function likely play an important role in various aspects of 
bipolar disorder, and enhancing mitochondrial function may represent a critical component 
for the treatment of the disorder (Quiroz et al., 2008). Changes in cerebral concentrations of 
N-acetyl aspartate (NAA), glutamate/glutamine, choline-containing compounds, myo-
inositol, lactate, phosphocreatine, phosphomonoesters, and intracellular pH in bipolar 
subjects were described (Yildiz-Yesiloglu & Ankerst, 2006). A hypothesis of mitochondrial 
dysfunction in bipolar disorder (Stork & Renshaw, 2005) was proposed and involved 
impaired oxidative phosphorylation, a resultant shift toward glycolytic energy production, a 
decrease in total energy production (decreased ATP production) and/or substrate 
availability, and changed concentrations of phosphomonoesters and altered phospholipid 
metabolism. 
Neuronal calcium homeostasis and calcium signalling regulate multiple neuronal functions, 
including synaptic transmission, neuronal plasticity and survival. The idea that altered 
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intracellular calcium signalling may be crucial for the molecular mechanisms leading to both 
schizophrenia and affective disorders was firstly suggested by Jimerson et al. (1979). 
Recently, disturbed calcium homeostasis has been studied in neurodegenerative (Wojda et 
al., 2008) and mood disorders. Mitochondrial DNA (mtDNA) mutations in the brain, 
associations of mtDNA polymorphisms and bipolar disorder and changes in gene 
expression related to mitochondria in the brain were observed (Kato, 2008). Calcium and 
mitochondrial dysfunction hypothesis of bipolar disorder offers that mtDNA 
polymorphisms/mutations or mtRNA deletions caused by nuclear gene mutations can 
cause mitochondrial dysregulation of calcium leading to symptoms of bipolar disorder 
(Kato & Kato, 2000; Kato, 2007, 2008).  
Mitochondrial hypothesis of bipolar affective disorder corresponds both to the neurotrophic 
and neuroplasticity hypothesis and to the inflammatory and neurodegenerative hypothesis 
because of an important role of mitochondria in cell energetic, regulation of calcium 
signalling pathway, production of reactive oxygen species and apoptosis, i.e. in processes 
determining synaptic plasticity, damage, repairing, survival or death of neurons. 
8. Conclusion 
The understanding of signalling pathways and their interconnections on the intracellular 
level is necessary to understand normal and damaged functions of the CNS. The exact 
neurochemical processes included in mood disorders have not yet been sufficiently 
explored; the main attention has been focused on changes in monoaminergic 
neurotransmitter systems and neuroplasticity. It is suggested that the changes in cognitive 
functions, learning, memory and the emotions during depression are caused by damaged 
neuroplasticity in hippocampus, amygdala and cerebral cortex. Changes in effects of 
neurotransmitters, hormones and growth factors probably cause changes of neuroplasticity; 
processes leading to changed neuroplasticity can be initiated by mitochondrial dysfunctions. 
The long-term administration of antidepressants leads to the effects similar to neurotrophic, 
as seen through the activation of transcription factors and increased gene expression of 
neurotrophins. Mood stabilizers, such as lithium and valproate, strongly activate also 
neurotrophic signal cascades and affect other signalling pathways. Intracellular processes 
among activation of receptor and increased gene expression of neurotrophins and other 
molecules have not yet been sufficiently clarified. Variability in these intracellular processes 
participates probably on interindividual differences of the response to treatment with 
antidepressant or in drug resistance.  
On the basis of clinical analyses and findings about signalling pathway components affected 
by administration of psychotropic drugs, studies of following components seem to be 
perspective: neurotransmitter receptors and transporters (especially for serotonin and 
norepinephrine), monoamine oxidases, adenylate cyclase and phosphoinositide cascade and 
MAPK pathway, mitochondrial dysfunctions, reactive oxygen species, nitric oxide and 
cytoplasmic calcium. The role of membrane potential and membrane lipids in the proper 
function of neuronal membranes should not be forgotten.  
Signal transduction is an amount of processes by which a cell converts one kind of signal 
into another. Neuronal signal transduction pathways involve neurotransmitter release, 
receptor activation and ordered sequence of biochemical reactions inside the cell. These 
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processes can be rapid in the case of ion-channels opening (milliseconds), slower in the case 
of the activation of second messenger systems (minutes), and slow in the case of gene 
expression (hours, and even days). As signal propagates from a relatively small initial 
stimulus to a final large response, the signal cascade involves increasing number of proteins 
and other molecules (Fišar & Hroudová, 2010). Many feedbacks and cross reactions are 
included in this amplification of the signal. Determining factors in signal transduction are 
input signals and concentration, activity and subcellular localization of participating 
molecules. All these factors are determined by previous history of the brain, and it is 
probable that participate in interindividual differences in response to the same stimuli. 
Regulation of critical intracellular signalling pathways plays a critical role in higher-order 
brain functions, which are altered in mood disorders, suggesting the involvement of 
dysfunctions of signalling pathways in the pathophysiology and the treatment of mood 
disorders (Gould et al., 2007). It can be concluded that both some structural deviations in 
neural networks and disturbances of signal transduction in certain neurons participate in 
development of mood disorders. It is assumed that novel biomarkers of mood disorders 
and/or predictors of efficiency of pharmacotherapy may be discovered on the basis of this 
research. 
It is suggested that environmental stress and genetic risk variants interact with each other in 
a complex manner to alter neural circuitry and evoke illness. Considering the existence of 
very rapid distinct shifts of mood (e.g. ultra-ultra-rapid cycling in bipolar affective disorder) 
(Kramlinger & Post, 1996), developmental and structural changes in neural networks could 
be considered as necessary condition for vulnerability to the development of pathological 
states of mood, whereas disturbances in signal transduction pathways in chemical synapses 
could be related to the onset of specific symptoms of mood disorder. Distinct shifts in mood 
and activity occur both in “normal” and “disordered” man and can be induced both by 
endogenous and external stimuli. Therefore, occurrence of several symptoms, their severity 
and time duration depend on the proportion of dysfunction of brain homeostatic 
mechanisms in various brain areas. It may be supposed that both normal and pathological 
shifts of mood (e.g. ultradian cycling or rapid switching from episode of depression to 
mania) are associated with changes in expression or activity of specific compounds of signal 
transduction pathways related to monoaminergic and glutamatergic systems. Identification 
of compounds of signal transduction that are primarily responsible for shifts of mood 
remains incomplete. We suppose that mild dysfunction of some mitochondrial functions 
might be basis for homeostatic imbalance in synapses during episodes of depression, 
hypomania, mania or the appearance of mixed states. 
Identification of biomarkers of mood disorders and factors capable of predicting the 
response to treatment with antidepressants has not been sufficiently successful (Balon, 1989; 
Joyce & Paykel, 1989; Fišar & Raboch, 2008). In accordance to actual neurochemical 
hypotheses of mood disorders, biological markers have been primarily found at the level of 
neurotransmitter concentrations, their metabolites or precursors. Subsequently, attention 
was shifted to the receptor systems, and since the 1990´s, intracellular processes have 
become of primary interest. There is evidence that growth factors, proinflammatory 
cytokines, endocrine factors, and metabolic markers contribute to the pathophysiology of 
major depressive disorder (Schmidt et al., 2011). The chance to find sensitive and specific 
biological predictors of antidepressant treatment has been increased, because of the 
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introduction of new molecular biology methods. These methods enable better observation of 
cellular processes connected with the transduction of nervous signals in the brain. The 
choice of parameters, which should be studied as perspective biological markers of mood 
disorders, has been derived first of all from new findings of signalling pathways involved in 
neurotransmission and from above mentioned neurochemical hypotheses of mood 
disorders. Following parameters could play a principal role in findings of biological markers 
of mood disorders: energetic metabolism and mitochondrial dysfunctions, activities of 
protein kinases, transcription factors, neurotrophins, proapoptotic and antiapoptotic factors, 
caspases, polyunsaturated fatty acids, membrane potential and fluidity, cortisol, melatonin, 
homocysteine, cytokines, SERT, Na+K+-ATPases, ROS, NO, cytoplasmic Ca2+ and CaM, 
enzymes GSK-3, COMT, MAO and cytochrome P450. According to the complexity and 
connectivity of signalling pathways involved in ethiopathogenesis of mood disorders, 
number of chosen parameters is not final.  
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